HCPs
Patients' stories
Get involved
Newly Diagnosed
Information
About ALK+ LC
Home
Who we are
What we do
Conference Booking
Early diagnosis
NICE
Shop
Contact us
Menu
Alectinib is a 2nd generation TKI developed by Roche. The recommended dose is 600mg taken twice daily. Along with Brigatinib, Alectinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients